<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7458227\results\search\testTrace\results.xml">
  <result pre="of International Concern.[2] So far, there has been no effective" exact="treatment" post="of COVID-19. Several potential drug candidates, including lopinavir/ritonavir (Kaletra),"/>
  <result pre="Lianhuaqingwen capsules), have been proposed.[8,9] It is perhaps clear that" exact="quarantine" post="alone may not be sufficient to prevent the spread"/>
  <result pre="spread of COVID-19, and the global impact of this viral" exact="infection" post="is 1 of heightening concern. Traditional Chinese medicine (TCM),"/>
  <result pre="with chemical and physical disinfectants, leading to a no nosocomial" exact="infection" post="report in the fight against SARS in 2003.[15] Existing"/>
  <result pre="COVID-19. In China, Chinese medicine (CM) is proposed as a" exact="treatment" post="option by national and provincial guidelines with substantial utilization.[18]"/>
  <result pre="During the outbreak of SARS, CM was introduced as a" exact="treatment" post="option since the early situation of epidemic in China."/>
  <result pre="clinical trials have proved the effectiveness of CM in the" exact="treatment" post="of SARS.[19] The sixth version of China national clinical"/>
  <result pre="the national guideline divided COVID-19 into medical observation period and" exact="treatment" post="period. The recommended formulation during medical observation period involved"/>
  <result pre="capsule and jin-hua-qing-gan granules, lian-hua-qing-wen capsule or shu-feng-jie-du capsule. The" exact="treatment" post="period is divided into 4 clinical stages with the"/>
  <result pre="may be a good additional candidate at least for trial" exact="treatment" post="considering the limited options available for COVID-19.[18] Early reported"/>
  <result pre="a convincing results for the application of TCM in the" exact="treatment" post="of COVID-19 due to the incomplete evidences of present"/>
  <result pre="searching the literature, all reviewers will discuss and determine the" exact="screening" post="criteria. After the screening requirements are clearly defined, the"/>
  <result pre="reviewers will discuss and determine the screening criteria. After the" exact="screening" post="requirements are clearly defined, the 2 reviewers will independently"/>
  <result pre="to contact the author of the article. 2.5.4 Measures of" exact="treatment" post="effect In this protocol, we will use 95% confidence"/>
  <result pre="analysis will be performed. 2.5.7 Assessment of heterogeneity For the" exact="detection" post="of heterogeneity, the I2 test will be used to"/>
  <result pre="Wuhan (2019-nCoV) Coronavirus. Am J Respir Crit Care Med2020;201:78.31658423 [8]LuHDrug" exact="treatment" post="options for the 2019-new coronavirus (2019-nCoV). Biosci Trends2020;14:6971.31996494 [9]WangMCaoRZhangLet"/>
  <result pre="a prospective cohort study. J Altern Complement Med2005;11:4955.15750363 [20]Diagnosis and" exact="treatment" post="of pneumonia caused by new coronavirus (trial version 6)"/>
  <result pre="Qingwen. J Tradit Chin Med2020;61:6559. [24]YaoKLiuMLiXet al.Retrospective clinical analysis on" exact="treatment" post="of novel coronavirus-infected pneumonia with traditional Chinese medicine Lianhua"/>
 </snippets>
</snippetsTree>
